AUTHORS
Veer Shah, Medical Student, Darshi Shah, MD, MPH2, Jaison Jain, MD3, Paolo Boffetta, MD, MPH4
AFFILIATIONS
1 Icahn School of Medicine at Mount Sinai, New York, New York, United States
2 Yale School of Medicine and Yale New Haven Hospital, New Haven, Connecticut, United States
3 New York University Grossman Long Island School of Medicine, Mineola, New York, United States
4 Renaissance School of Medicine at Stony Brook University, Stony Brook, New York, United States
ABSTRACT
INTRODUCTION:
Management of mantle cell lymphoma (MCL) has evolved substantially over the past two decades with the introduction of rituximab-based chemoimmunotherapy, bendamustine-containing regimens, Bruton tyrosine kinase (BTK) inhibitors, and more recently, CAR T-cell therapy and other immunotherapeutic approaches. Although these advances have significantly altered the treatment landscape and improved clinical outcomes, contemporary population-based studies evaluating survival across successive therapeutic eras remain limited, particularly those distinguishing cancer-specific mortality from competing non-cancer causes of death. Hence, we evaluated temporal trends in overall and cancer-specific survival among patients with MCL using competing-risks analysis and identified prognostic factors of adverse outcomes across successive treatment eras, using a large population-based cohort.
METHODS:
Using the SEER 21 Registries database, we identified patients with mantle cell lymphoma (MCL; ICD-O-3 9673/3, malignant behavior) diagnosed during 2000-2023. Eligible patients had a known age at diagnosis, MCL as their only or first primary malignancy, and survival ≥1 month. Autopsy- or death certificate-only cases were excluded. Patients were grouped into three prespecified eras reflecting major changes in MCL therapeutic landscape: the chemoimmunotherapy era, including R-CHOP and rituximab maintenance (2000-2012; n=9,058), the BTK inhibitor era (2013-2019; n=6,729), and the cellular/immunotherapy era, including CAR T-cell therapy and bi-specific antibodies (2020-2023; n=3,949). Overall survival (OS) and cause-specific survival (CSS) were estimated by Kaplan-Meier and compared by log-rank test. Multivariable Cox proportional-hazards models adjusted for age, sex, race/ethnicity (non-Hispanic [NH] Black, Hispanic, NH White, Asian Pacific Islander, American Indian and Alaska Native), disease stage (localized, regional, distant, unknown), residence (metropolitan vs. non-metropolitan), marital status (married, single, divorced, widowed, separated), and area-level median income. As patients with MCL experience substantial mortality from non-cancer-related causes, the Fine & Gray (F&G) competing risk model was applied to accurately distinguish CSM and mortality from other causes. A one-primary-only sensitivity analysis (N=16,905) was also performed to assess the robustness of our findings by excluding patients with multiple primary malignancies.
RESULTS:
Of the 19,736 identified patients with MCL (ICD-O-3 9673/3) diagnosed between 2000-2023, median OS was 70 months; 5-year OS and CSS were 53.5% and 63.5%, respectively. Survival improved steadily across periods: 2-year CSS rose from 75.5% (2000-2012) to 80.3% (2013-2019) to 82.0% (2020-2023), with corresponding gains in 2-year OS (70.7% to 74.8% to 75.3%).
After adjusting for confounding variables, later periods retained an independent advantage (CSS HR 0.68 [95% CI 0.65-0.72] for 2013-2019; 0.65 [0.60-0.71] for 2020-2023 vs 2000-2012), an adjusted ~4%/year decline in cause-specific mortality hazard (HR 0.96/yr, p<0.001). Older age (HR 1.59 per 10 years [1.56-1.63]) and advanced stage (distant HR 2.01 [1.81-2.24]; unknown HR 2.09) were the strongest adverse predictors; female sex was protective (HR 0.78 [0.74-0.82]).
Fine-Gray competing risks analysis showed that temporal survival improvements were driven primarily by reduced cancer-specific mortality (CSM; 2013-2019: sHR 0.64, 95% CI 0.61-0.67; 2020-2023: sHR 0.56, 95% CI 0.52-0.61), rather than competing non-cancer causes of deaths. Effect estimates were also stable in the one-primary-only sensitivity analysis (N=16,905), with similar period improvements (2013-2019: HR 0.63; 2020-2023: HR 0.58 vs 2000-2012)
CONCLUSIONS:
Population-level survival in MCL improved across successive therapeutic eras, driven primarily by reductions in CSM. Despite these improvements, older age and advanced stage remained the strongest independent predictors of adverse outcomes. These improvements remained significant after adjustment for case mix. Given the limitations of SEER, these findings likely reflect broader changes in clinical practice and the adoption of novel therapies rather than the effects of any individual treatment. Validation in treatment-level datasets with longer follow-up is warranted to define the contribution of specific therapeutic advances and to identify patient subgroups most likely to benefit from contemporary treatment strategies.
DISCLOSURES
Veer Shah, Medical Student: No relevant conflicts of interest to declare.